Product Description
LB1908 is an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy selectively targeting Claudin 18.2 through a high-affinity VHH antibody for the treatment of adults with relapsed or refractory gastric, esophageal (including gastro- esophageal junction) or pancreatic cancers. (Sourced from: https://legendbiotech.com/legend-news/legend-biotech-announces-u-s-fda-clearance-of-ind-application-for-solid-tumor-car-t-lb1908-for-relapsed-or-refractory-gastric-esophageal-and-pancreatic-cancers/)
Mechanisms of Action: CAR-T,CLDN18.2
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Legend Biotech
Company Location: SOMERSET NJ 08873
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LB1908-1001 | P1 |
Recruiting |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer|Pancreatic Cancer |
2025-07-01 |